Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback

Innoviva, Inc.

2025-Q3 EPS reported $1.35 revenue$296,715,000

Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).
Net income $89.9M ($1.30 basic EPS) vs $1.2M ($0.02) in Q3 2024; driven by $62.3M fair-value gains on equity investments.
Income from operations $34.6M, down 20% primarily due to non-recurring R&D expense.
Board authorized $125M share repurchase program; $192.5M of convertible notes converted into 11.1M shares in August.
ZEVTERA U.S. launch in July; zoliflodacin PDUFA Dec 15, 2025; investments: Armata $15M, Lyndra $10.2M, Beacon Biosignals $17.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.